Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04572243 · ClinicalTrials.gov registry record · Phase 3
A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome
A Phase 3 study, sponsored by Eisai.
- Terminated
- Registry status
- Phase 3
- Development phase
- 22
- Enrollment target
NCT04572243 is a Phase 3 study that was terminated before completion, run by Eisai. The registered enrollment target is 22 participants.
The verdict
NCT04572243, a Phase 3 study, was terminated before completion, sponsored by Eisai.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 22 participants
- Enrollment target
Study Summary
The primary purpose of the study is to demonstrate that lorcaserin has superior efficacy compared to placebo on percent change in frequency of convulsive seizures per 28 days in participants with Dravet syndrome.
Interventions
- DRUG Placebo
- DRUG Lorcaserin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2020-09-23 |
| Est. Completion | 2024-08-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04572243
The ClinicalTrials.gov registry entry for NCT04572243 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04572243 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04572243 about?
NCT04572243 is a clinical study titled "A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome". The primary purpose of the study is to demonstrate that lorcaserin has superior efficacy compared to placebo on percent change in frequency of convulsive seizures per 28 days in participants with Dravet syndrome.
What is the current status of trial NCT04572243?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 22 participants. The study started on 2020-09-23. Estimated completion is 2024-08-15.
What interventions are being tested in trial NCT04572243?
The interventions under investigation include: Placebo (DRUG), Lorcaserin (DRUG).
Who is sponsoring clinical trial NCT04572243?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.